Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
90.00
+0.35 (0.39%)
At close: Apr 20, 2026

HKG:2659 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
49.166.166.93
Revenue Growth (YoY)
697.99%-11.11%-
Cost of Revenue
5.411.140.15
Gross Profit
43.755.026.78
Selling, General & Admin
108.13115.5447.58
Research & Development
248.24250.73132.55
Other Operating Expenses
-3.59-1.77-6.68
Operating Expenses
352.79364.51173.45
Operating Income
-309.04-359.49-166.66
Interest Expense
-5.97-4.56-3.66
Interest & Investment Income
6.144.657.9
Earnings From Equity Investments
-0.24-0.61-0.92
Currency Exchange Gain (Loss)
-7.471.192.97
Other Non Operating Income (Expenses)
-25.19-5.57-
EBT Excluding Unusual Items
-341.77-364.38-160.37
Gain (Loss) on Sale of Investments
3.22--
Gain (Loss) on Sale of Assets
0.01-0.08-0.03
Legal Settlements
-56.76--
Pretax Income
-395.3-364.46-160.4
Income Tax Expense
--0.02-0
Net Income
-395.3-364.43-160.4
Net Income to Common
-395.3-364.43-160.4
Shares Outstanding (Basic)
290268253
Shares Outstanding (Diluted)
290268253
Shares Change (YoY)
8.43%5.82%-
EPS (Basic)
-1.36-1.36-0.63
EPS (Diluted)
-1.36-1.36-0.63
Free Cash Flow
-333.41-338.06-276.58
Free Cash Flow Per Share
-1.15-1.26-1.09
Gross Margin
89.00%81.49%97.85%
Operating Margin
-628.68%-5835.80%-2404.96%
Profit Margin
-804.18%-5916.12%-2314.50%
Free Cash Flow Margin
-678.27%-5487.91%-3991.02%
EBITDA
-273.91-329.76-146.12
D&A For EBITDA
35.1229.7320.55
EBIT
-309.04-359.49-166.66
Source: S&P Global Market Intelligence. Standard template. Financial Sources.